Post-PCI Ticagrelor Monotherapy in High-Risk Bleeding

In patients at high risk of bleeding undergoing coronary PCI and after completing 3-month DAPT with no events, you may discontinue aspirin and follow up with ticagrelor monotherapy. This will significantly reduce bleeding without increasing ischemic events. 

Monoterapia de ticagrelor post angioplastia en alto riesgo de sangrado

With this strategy, the greater the risk of bleeding, the greater the absolute reduction of bleeding.

Patients at high risk of bleeding are a prevalent population among PCI patients, which is why early discontinuation of one of the antiplatelet drugs results enticing. 

Actually, abandoning an antiplatelet after DAPT has become standard, and the evidence in favor of this keeps piling up. The only remaining question is what antiplatelet to stop. The present study, the TWILIGHT, discontinued aspirin.

This prespecified analysis of the TWILIGHT specifically assessed patients at high risk of bleeding included in the general study (nearly 20% of the population from the original study was qualified as high risk according to BARC criteria).

After 3 months of ticagrelor + aspirin, patients were randomized to continuing with both drugs for 12 months vs. stopping aspirin. 


Read also: The Most Read Articles of 2021: COVID-19.


Ticagrelor monotherapy significantly reduced the incidence of primary end point (BARC bleeding 2, 3 or 5) compared against the dual scheme (6.3% vs. 11.4%; HR 0.53, CI 95% 0.35 to 0.82). 

Patients at lower risk also saw benefits when interrupting aspirin, even though with different magnitude. (3.5% vs. 5.9%; HR 0.59, CI 95% 0.46 to 0.77).

A similar pattern but even more significant in favor of ticagrelor monotherapy was observed when looking only at BARC bleeding 3 and 5.


Read also: Women Present Lower Risk of Sport Related Sudden Death Compared to Men.


The flipside (ischemic events) saw no effects whatsoever. Death, MI, and stroke resulted identical between branches, regardless of bleeding risk. 

Conclusion

After 3 months of dual antiaggregation therapy with aspirin and ticagrelor, it is possible to stop aspirin and continue only with ticagrelor. This strategy significantly reduces bleeding and does not modify ischemic events. Absolute reduction of bleeding is even higher among patients at high risk of bleeding. 

ehab702

Original Title: Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronaryintervention: TWILIGHT-HBR.

Reference: Javier Escaned et al. Eur Heart J. 2021 Dec 1;42(45):4624-4634. doi: 10.1093/eurheartj/ehab702.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...